Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.

@article{Wei2019CosteffectivenessAO,
  title={Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.},
  author={Xiaoxia Wei and Jiaqin Cai and H. Sun and N. Li and Chenxia Xu and G. Zhang and Yuxia Sui and J. Zhuang and B. Zheng},
  journal={Pharmacogenomics},
  year={2019},
  volume={20 4},
  pages={
          241-249
        }
}
  • Xiaoxia Wei, Jiaqin Cai, +6 authors B. Zheng
  • Published 2019
  • Medicine
  • Pharmacogenomics
  • AIM To assess the cost-effectiveness of UGT1A1*6/*28 genotyping compared with no genotyping or no dose adjustment before irinotecan administration in China. MATERIALS & METHODS A decision tree model was developed to evaluate costs and health outcomes represented as quality-adjusted life years gained. Model inputs for the frequency of genotypes, the probability of neutropenia under FOLFIRI chemotherapy and direct costs and utilities were obtained from published sources. One-way sensitivity… CONTINUE READING
    3 Citations

    References

    SHOWING 1-10 OF 28 REFERENCES
    Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.
    • 29
    • PDF
    Cost Evaluation of Irinotecan‐Related Toxicities Associated With the UGT1A1*28 Patient Genotype
    • 22
    Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
    • 9